Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.41 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30088390 | 1.00 | IGF1R (0.51) | IGF1RMEN1KMT2AMAPK8CDK19 | |
| SCHEMBL25056307 | 0.86 | MEN1 (0.52) | IGF1RMEN1KMT2AMAPK8CDK19 | |
| SCHEMBL6176285 | 0.83 | IGF1R (0.48) | IGF1RMEN1KMT2AMAPK8CDK19 | |
| SCHEMBL17544687 | 0.81 | IGF1R (0.55) | IGF1RMEN1KMT2AMAPK8CDK19 | |
| SCHEMBL30833628 | 0.81 | IGF1R (0.46) | IGF1RMEN1KMT2AMAPK8CDK19 | |
| SCHEMBL30833796 | 0.81 | IGF1R (0.46) | IGF1RMEN1KMT2AMAPK8CDK19 | |
| SCHEMBL26506627 | 0.80 | IGF1R (0.68) | IGF1RMAPK8CDK19ALKGSK3B | |
| SCHEMBL32684519 | 0.78 | KMT2A (0.41) | IGF1RMEN1KMT2AMAPK8CDK19 | |
| SCHEMBL30833802 | 0.78 | IGF1R (0.55) | IGF1RMEN1KMT2AMAPK8CDK19 | |
| SCHEMBL24260666 | 0.78 | IGF1R (0.55) | IGF1RMEN1KMT2AMAPK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| CN-115515589-A | ULK1/2 inhibitors and methods of use thereof | 萨克生物研究学院 | 2022-12-23 | — | — | CN | disclosed |
| EP-4103182-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Salk Institute for Biological Studies (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3185868-B1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INST FOR BIOLOGICAL STUDI (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2021163629-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021163629-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-08-19 | — | — | WO | disclosed |
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-08-15 | — | — | US | disclosed |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-05-23 | — | — | US | disclosed |
| US-10266549-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3185868-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266549-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | IGF1R 1213/4885MEN1 1586/4885KMT2A 3395/4885 |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | IGF1R 2282/4885MEN1 2093/4885KMT2A 3058/4885 |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | IGF1R 1164/4885MEN1 2139/4885KMT2A 3500/4885 |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | IGF1R 1164/4885MEN1 2139/4885KMT2A 3500/4885 |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | IGF1R 1164/4885MEN1 2139/4885KMT2A 3500/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | IGF1R 1213/4885MEN1 1586/4885KMT2A 3395/4885 |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | IGF1R 1164/4885MEN1 2139/4885KMT2A 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.